New radiotheranostic pair shows promise for detecting and treating metastatic kidney cancer
Source Summary
Researchers have developed 68Ga/177Lu-NYM096, a radiotheranostic pair that can identify tumors and deliver targeted radiotherapy to patients with metastatic clear cell renal cell carcinoma. The small-molecule compound approach reduces toxicity issues associated with conventional treatment, offering a safe and feasible strategy for end-stage disease. The findings were published in The Journal of Nuclear Medicine's September issue.
Why it matters
This radiotheranostic approach addresses a critical need in metastatic kidney cancer treatment by combining tumor detection and targeted radiotherapy while reducing toxicity, offering a new option for patients with end-stage disease.
